The Pharmacists' Defence Association (PDA) is probing major concerns arising from Boots' communications to pharmacists regarding the company's recently
announced pension arrangements.
In November, Walgreens Boots Alliance (WBA), the parent company of Boots, transferred the Boots employees' pension scheme to the financial service provider Legal
and General (L&G) in a £4.8 billion deal.
Boots notified staff that terms allowing an unreduced pension from age 60 have ceased immediately, following its agreement with L&G.
The PDA highlighted member concerns regarding Boots management's announcement that an unreduced pension from the age of 60 is a discretionary benefit and not
guaranteed under the Boots Pension Scheme (BPS), contrary to some members' assumptions.
Haleon, the consumer healthcare giant behind brands like Sensodyne toothpaste and Advil painkillers, has announced plans to shut down its Maidenhead
manufacturing site in the UK.
This decision will impact 435 employees and comes as part of a broader strategic realignment of the company's global manufacturing operations according to BBC.
The Maidenhead facility, which has been in operation for years, manufactures some of Haleon's most popular oral health products, including Sensodyne and Parodontax.
However, following a comprehensive review of its manufacturing capabilities, the company has concluded that the site is no longer economically viable.
In a statement issued by a spokesperson for Haleon, they stated, "Following a strategic review of our global manufacturing capabilities, we have determined that
our Maidenhead site is no longer a viable option for the manufacture of our products."